Cipla

Indian pharmaceutical major Cipla has initiated a recall of a cancer treatment drug in the United States after regulatory authorities identified manufacturing-related concerns. According to information released by the U.S. Food and Drug Administration, the recall was issued as part of routine quality surveillance designed to ensure the safety and efficacy of medicines distributed in the American market. While the recall does not necessarily indicate widespread harm to patients, it highlights the stringent compliance standards required for pharmaceutical companies operating globally.

Cipla reported a steep year-on-year decline in net profit for the third quarter, reflecting margin pressure despite stable operational performance. The pharmaceutical major posted a 57% drop in consolidated profit to Rs 676 crore, weighed down by higher input costs, normalization in pricing, and a challenging global demand environment. While revenue streams remained resilient across key markets, profitability was constrained by elevated expenses and a tougher competitive landscape. Management maintained a cautious outlook, emphasizing operational efficiency and portfolio optimization.

Cipla has unveiled an inhalable insulin formulation, marking a significant innovation in diabetes care. The new product offers patients a non-invasive alternative to traditional injectable insulin, potentially improving adherence and quality of life for individuals with Type 1 and Type 2 diabetes. Analysts highlight that this launch positions Cipla at the forefront of advanced therapeutic solutions in India’s growing diabetes market, which is witnessing rising prevalence and demand for patient-friendly treatments.

Global pharmaceutical leader Pfizer has entered a strategic partnership with Indian pharma giant Cipla to jointly market four of its major brands in India. The alliance aims to leverage Cipla’s extensive domestic distribution network and Pfizer’s internationally recognized products, enhancing reach, sales growth, and patient access. Analysts see the deal as a strategic alignment that strengthens both companies’ market positioning in India’s rapidly expanding healthcare sector.

Cipla has expanded its chronic care portfolio with the launch of Yurpeak, a new therapy targeting obesity and diabetes—two of the fastest-growing health challenges in India. The company is positioning the drug as part of a broader strategy to address rising metabolic disorders, which have seen a sharp increase driven by lifestyle changes and urbanisation. With this launch, Cipla aims to strengthen its position in the high-potential metabolic care segment and provide clinicians with more advanced treatment options.

Cipla, a leading pharmaceutical company, has inaugurated a state-of-the-art Lung Health Diagnostics Center in India, marking a strategic step to enhance respiratory healthcare services. The center will provide comprehensive diagnostic solutions for lung-related ailments, combining advanced imaging, pulmonary function testing, and clinical evaluation under one roof. This initiative aligns with Cipla’s commitment to improving patient outcomes, particularly amid rising respiratory health concerns in India.

Global pharmaceutical giant Lilly has partnered with Indian healthcare leader Cipla to distribute the diabetes medication Yurpeak across India. The collaboration is poised to enhance access to innovative treatments for patients managing type 2 diabetes, reflecting a growing trend of strategic alliances between multinational and domestic pharmaceutical companies.

Cipla Ltd., one of India’s leading pharmaceutical companies, reported a robust financial performance for the first quarter of FY2025, posting a 10% year-on-year increase in consolidated profit after tax (PAT), reaching Rs. 1,298 crore. The company’s performance was buoyed by strong sales in key markets such as North America and India, as well as steady progress in its respiratory and complex generics portfolio.

Indian pharmaceutical equities plunged on June 17, as investor sentiment deteriorated following US President Donald Trump’s renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index dropped over 2%, marking it as the day’s worst-performing sector. With India being one of the largest exporters of generic drugs to the US, analysts fear a significant impact on margins, revenues, and forward guidance for key industry players. Major firms like Cipla, Dr.

Cipla, the renowned pharmaceutical company, has been awarded a water positive certification by Bureau Veritas for its India operations, signaling a significant milestone in its sustainability journey. The certification reflects Cipla’s commitment to responsible water usage, with 67% of its domestic manufacturing units adopting Zero Liquid Discharge (ZLD) systems. Additionally, the company has reduced its overall water withdrawal by 13.1% compared to FY 2019-20, with half of the withdrawn water being recycled and reused.